Berkeley Heights, NJ - June 13, 2003
- Genta Incorporated (Nasdaq: GNTA) today announced that the
Company will audio webcast its 2003 Annual Meeting of Shareholders.
The meeting will be held on Wednesday, June 25, 2003, at 11:00 am
EST, at The Hotel Westminster, Livingston, NJ.
A live audio webcast of the presentation can be accessed. Please
register for the webcast at
http://events.reflectsystems.com/clients/worldbridge/20030625/
. A replay will be available for 90 days following the
presentation.
Shareholders wishing to attend the meeting may call the hotel at
973-533-0600 for directions and information.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on oligonucleotides (RNA/DNA-based medicines) and small
molecules. Genasense
TM
(oblimersen sodium), the Company"s lead compound from its
oligonucleotide program, is being developed with Aventis and is
currently undergoing late-stage, Phase 3 clinical testing. The
leading drug in Genta's small molecule program is Ganite
TM
(gallium nitrate injection), which the Company intends to launch
later this year for treatment of cancerrelated hypercalcemia that
is resistant to hydration. For more information about Genta, please
visit our website at:
http://www.genta.com/
.
This press release and the webcast to follow contain
forward-looking statements with respect to business conducted by
Genta Incorporated. By their nature, forward-looking statements
and forecasts involve risks and uncertainties because they relate
to events and depend on circumstances that will occur in the
future. There are a number of factors that could cause actual
results and developments to differ materially. For a discussion
of those risks and uncertainties, please see the Company"s Annual
Report/Form 10-K for 2002.
SOURCE: Genta Incorporated
